A really interesting paper which used real world evidence to quantify outcomes and treatment burden of anti-vascular endothelial growth factor (anti-VEGF) treatment for diabetic macular oedema in phakic patients.
Our UK-based work confirmed earlier retrospective real world studies of anti-VEGF treatments which have reported lower injection frequency and functional gains than randomised clinical trials and the importance of baseline best recorded visual acuity (BRVA) in predicting outcomes.
Continuing treatment beyond 6 months in patients with a suboptimal response imposes a large treatment burden with only modest clinical benefit. In suboptimal responders to anti-VEGF, consideration of early switch to longer acting steroid treatments may help to reduce treatment burden, whilst maintaining or improving vision.
The paper is available as Open Access in Eye, https://pubmed.ncbi.nlm.nih.gov/37542174/
Hot off the press
We've just published a paper in the Journal of Medical Economics showing that adding the Parkinson’s KinetiGraph (the PKG, a wrist-worn movement recording device that collates continuous, objective, data during daily activities in people with Parkinson’s disease (PD) providing a report for clinicians) to standard monitoring of PD is a cost-effective option.